Longitudinal algorithm may detect ovarian cancer earlier

December 21, 2012
Longitudinal algorithm may detect ovarian cancer earlier
Compared with a single-threshold rule, a parametric empirical Bayes longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

(HealthDay)—Compared with a single-threshold (ST) rule, a parametric empirical Bayes (PEB) longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

Charles W. Drescher, M.D., of the Fred Hutchinson Cancer Research Center in Seattle, and colleagues compared an ST rule with a PEB longitudinal screening algorithm in a retrospective evaluation of preclinical CA125 values measured annually in 44 participants with incident from the Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial.

The researchers found that, in many cases, ovarian cancer was detected earlier using the PEB algorithm, compared to using an ST rule. At a specificity of 99 percent, corresponding to an ST rule CA125 cut-off of ≥35 U/mL used in the PLCO trial, use of the PEB algorithm would have identified 20 percent of cases earlier. The PEB indicated abnormal CA125 values among these cases 10 months earlier and at a lower CA125 concentration (42 percent lower; 20 U/mL) than an ST rule cut-off. As the specificity of screening was reduced, there was an increase in the proportion of cases detected earlier by PEB.

"Our results demonstrated that, for ovarian by using , the PEB longitudinal algorithm detected ovarian cancer earlier than an ST rule in a statistically significant and meaningful proportion of cases," the authors write. "This observation was consistent across a range of specificities relevant for a first-line test in a multimodal ."

Explore further: FDA clears biomarker test for ovarian cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

FDA clears biomarker test for ovarian cancer

September 6, 2011

Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

Recommended for you

Scientists block breast cancer cells from hiding in bones

May 25, 2016

Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise ...

Genetic sequencing reveals drug resistance growth

May 25, 2016

The rate at which genetically mutated cancer cells grow may help explain why patients with a common form of leukemia develop treatment resistance, according to new research led by a Weill Cornell Medicine investigator. The ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.